Physician profile
Sandra Suderman
NPI 1679666077
$3,661.51
in general payments reported to CMS, 2019-2025
27 companies · $1,156 in 2025
The $1,156 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $43.56 · 2022: $87.15 · 2023: $1,029 · 2024: $1,346 · 2025: $1,156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,530.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $844.62 | 2023-2025 | |
| Lilly USA, LLC | $606.62 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $459.46 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $289.54 | 2021-2025 | |
| Abbott Laboratories | $212.66 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $175.72 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Otsuka America Pharmaceutical, INC. | $129.78 | 2024-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.78 | 2022-2025 | Jardiance |
| Dexcom, INC. | $89.36 | 2021-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $83.11 | 2024-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $82.90 | 2023-2024 | Trelegy Ellipta |
| Shield Therapeutics INC | $72.41 | 2025 | |
| Novartis Pharmaceuticals Corporation | $52.22 | 2023-2024 | |
| Astellas Pharma US INC | $51.03 | 2025 | Veozah |
| Inspire Medical Systems, INC. | $49.87 | 2025 | Inspire |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $45.92 | 2024-2025 | Ibsrela |
| Exact Sciences Corporation | $45.41 | 2024-2025 | Cologuard Collection Kit |
| Janssen Biotech, INC. | $37.02 | 2024 | Tremfya |
| Dermavant Sciences, INC. | $33.73 | 2023 | Vtama |
| Lundbeck LLC | $33.11 | 2024 | Rexulti |
| Boston Scientific Corporation | $28.05 | 2024 | Watchman Flx |
| Alexion Pharmaceuticals, INC. | $24.95 | 2023 | |
| Noven Therapeutics, LLC | $22.03 | 2023 | Xelstrym |
| Alnylam Pharmaceuticals INC. | $20.20 | 2025 | Givlaari |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.51 | 2024 | Caplyta |
| Medtronic, INC. | $17.70 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.80 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Suderman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.